Year 2019 / Volume 111 / Number 12
Original
Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer

941-945

DOI: 10.17235/reed.2019.6460/2019

Yan Zhang, Min Tang, Xiao-Ge Wang, Jin-Hua Gu, Li-Na Zhou, Jun Jin, Ping Li, Li-Qiang Wang, Min-Bin Chen,

Abstract
Background: interleukin-37 (IL-37) is as a natural suppressor of the innate inflammatory and immune responses. It has also been reported to be involved in carcinogenesis and metastasis. The present case-control study was designed to investigate the role of serum levels of IL-37 in patients with gastric cancer. Methods: serum IL-37 levels were determined using the enzyme-linked immunosorbent assay in 180 patients diagnosed with gastric cancer and 100 healthy controls. The association between IL-37 levels and clinical factors was assessed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters in gastric cancer. Results: serum IL-37 levels in gastric cancer patients (5.606 ± 0.837 pg/ml) were significantly higher than those in healthy controls (2.364 ± 0.210 pg/ml, p < 0.001). High serum IL-37 levels were related to a poorly differentiated histologic type (p = 0.046) and advanced T stage (p = 0.003). The Kaplan-Meier survival analysis indicated that the high-IL-37 group had a poorer overall survival and progression-free survival (overall survival [OS]: 39.0 months vs 13.0 months, p < 0.001, progression-free survival [PFS]: 25.0 months vs 10.0 months, p < 0.001). Multivariate analyses showed serum IL-37 to be an independent prognostic factor for gastric cancer patients (OS: hazard ratios [HR] = 1.842, 95% CI: 1.190-2.854, p = 0.006; PFS: HR = 1.547, 95% CI: 1.014-2.359, p = 0.043). Conclusions: in conclusion, serum IL-37 levels were associated with poor overall survival and progression-free survival in gastric cancer patients. IL-37 may be a potential predictor of prognosis in gastric cancer.
Share Button
New comment
Comments
No comments for this article
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.
2. Xu G, Feng F, Liu S, et al. Clinicopathological features and prognosis in elderly gastric cancer patients: a retrospective cohort study. OncoTargets and therapy. 2018;11:1353-62.
3. Chen HM, Fujita M. IL-37: a new player in immune tolerance. Cytokine. 2015;72(1):113-4.
4. Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunological reviews. 2018;281(1):179-90.
5. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proceedings of the National Academy of Sciences of the United States of America. 2015;112(8):2497-502.
6. Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nature communications. 2014;5:4711.
7. Conti P, Gallenga CE, Ronconi G, et al. Activation of mast cells mediates inflammatory response in psoriasis: Potential new therapeutic approach with IL-37. Dermatologic therapy. 2019:e12943.
8. Li Y, Wang Z, Yu T, et al. Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PloS one. 2014;9(9):e107183.
9. Chen B, Huang K, Ye L, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity. Journal of translational medicine. 2015;13:36.
10. Ding VA, Zhu Z, Xiao H, et al. The role of IL-37 in cancer. Medical oncology. 2016;33(7):68.
11. Huo J, Hu J, Liu G, et al. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Archives of gynecology and obstetrics. 2017;295(2):459-65.
12. Jiang Y, Wang Y, Liang L, et al. IL-37 mediates the antitumor activity in renal cell carcinoma. Medical oncology. 2015;32(11):250.
13. Jia H, Liu J, Han B. Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases. BioMed research international. 2018;2018:3058640.
14. Yang L, Zhang J, Tao J, et al. Elevated serum levels of Interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2015;123(12):1025-31.
15. Farrokhi M, Rezaei A, Amani-Beni A, et al. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica. Acta neurologica Belgica. 2015;115(4):609-14.
16. Zhao JJ, Pan QZ, Pan K, et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Scientific reports. 2014;4:5177.
17. Jiang M, Wang Y, Zhang H, et al. IL-37 inhibits invasion and metastasis in non-small cell lung cancer by suppressing the IL-6/STAT3 signaling pathway. Thoracic cancer. 2018;9(5):621-9.
18. Shuai X, Wei-min L, Tong YL, et al. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Scientific reports. 2015;5:14478.
19. Wu W, Wang W, Wang Y, et al. IL-37b suppresses T cell priming by modulating dendritic cell maturation and cytokine production via dampening ERK/NF-kappaB/S6K signalings. Acta biochimica et biophysica Sinica. 2015;47(8):597-603.
20. von Boehmer H, Daniel C. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nature reviews Drug discovery. 2013;12(1):51-63.
Related articles

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Review

Immunotherapy in hepatocellular carcinoma

DOI: 10.17235/reed.2022.8876/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Digestive Diseases Image

Villous atrophy, an endoscopic and diagnostic challenge

DOI: 10.17235/reed.2021.8169/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Review

Practical management of primary biliary cholangitis

DOI: 10.17235/reed.2021.8219/2021

Original

Can we optimize CEA as a response marker in rectal cancer?

DOI: 10.17235/reed.2020.7321/2020

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Original

Chronic diarrhea due to autoimmune enteropathy

DOI: 10.17235/reed.2020.7218/2020

Letter

Primary squamous cell carcinoma of the stomach: a rare entity

DOI: 10.17235/reed.2018.5900/2018

Editorial

The right colon challenge

DOI: 10.17235/reed.2018.5544/2018

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Digestive Diseases Image

Immune mediated colitis caused by lung cancer treatment with atezolizumab

DOI: 10.17235/reed.2017.5060/2017

Letter to the Editor

Neuroendocrine tumors of the pancreas: keys issues in dealing with heterogeneity

DOI: 10.17235/reed.2017.4997/2017

Letter to the Editor

Pancreatic neuroendocrine tumors. Prognostic factors

DOI: 10.17235/reed.2017.5109/2017

Editorial

Pancreas neuroendocrine tumors - not so rare or benign

DOI: 10.17235/reed.2016.4672/2016

Letter to the Editor

Alopecia areata as a paraneoplastic syndrome of gastric cancer

DOI: 10.17235/reed.2016.4455/2016

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Citation tools
Zhang Y, Tang M, Wang X, Gu J, Zhou L, Jin J, et all. Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer. 6460/2019


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1099 visits.
This article has been downloaded 184 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 22/06/2019

Accepted: 31/07/2019

Online First: 13/11/2019

Published: 05/12/2019

Article revision time: 33 days

Article Online First time: 144 days

Article editing time: 166 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology